What is the recommended dosing regimen and monitoring plan for subcutaneous furosemide in a patient with cardiac amyloidosis who cannot receive oral or intravenous diuretics?

Subcutaneous Furosemide for Cardiac Amyloidosis

For patients with cardiac amyloidosis who cannot receive oral or intravenous diuretics, subcutaneous furosemide at 80 mg (30 mg over 1 hour, then 12.5 mg/hour for 4 hours) using novel pH-neutral formulations is the recommended approach, with daily monitoring of weight, blood pressure, and renal function. 1, 2, 3

Dosing Regimen

The FDA-approved subcutaneous furosemide formulation (Furoscix) delivers:

• Initial bolus: 30 mg over the first hour
• Maintenance infusion: 12.5 mg/hour for 4 hours
• Total dose: 80 mg over 5 hours 2, 3

This regimen achieves 99.7-112% bioavailability compared to intravenous furosemide, with equivalent diuresis and natriuresis 3. The pharmacokinetic modeling demonstrates appropriate exposure across different body weights, with clearance of 1.55 mL/min/kg 2.

Critical Considerations for Cardiac Amyloidosis

Cardiac amyloidosis patients require exceptionally cautious volume management due to:

• Preload dependence: The restrictive physiology makes these patients highly sensitive to volume depletion 1, 4
• Autonomic dysfunction: Impairs compensatory responses to diuresis 1, 4
• Poor tolerance of standard heart failure therapies: Beta-blockers and ACE inhibitors often worsen symptoms 5, 4

Start with lower diuretic doses than typical heart failure patients and titrate slowly. The goal is symptom relief without inducing hypotension or renal dysfunction 1, 4.

Monitoring Plan

Daily Monitoring (First Week):

• Weight: Target 0.5-1 kg daily loss maximum 6
• Blood pressure: Watch for orthostatic hypotension (common with autonomic neuropathy)
• Symptoms: Assess dyspnea, orthopnea, peripheral edema
• Urine output: Document response to therapy

Laboratory Monitoring:

• Electrolytes and creatinine: Check within 1-3 days of initiation, then at least weekly 7
• Serum albumin: Important for gauging edema mobility 6
• Potassium: Maintain ≥4 mmol/L 8

Acceptable Changes During Diuresis:

• Creatinine elevation up to 30% from baseline is common and acceptable during effective decongestion 6, 7
• Mild hypotension is tolerable if patient remains asymptomatic 9

Adjunctive Strategies

If subcutaneous furosemide alone is insufficient:

1. Add thiazide diuretic (metolazone 2.5-5 mg once daily) for synergistic effect 6, 7
2. Compression stockings: Particularly helpful given autonomic dysfunction and peripheral edema 1
3. Consider torsemide or bumetanide if switching routes, as they have better oral bioavailability than furosemide in intestinal edema 1

Advantages of Subcutaneous Route

Novel pH-neutral formulations offer:

• Minimal skin irritation (unlike conventional subcutaneous furosemide which caused reactions in 3-23% of patients) 3
• Home administration capability: Reduces hospitalization burden 10, 11, 12
• Consistent absorption: Bypasses intestinal edema that impairs oral furosemide 11, 3
• Equivalent efficacy to IV: Similar diuresis, natriuresis, and weight loss 3, 12

Common Pitfalls to Avoid

1. Over-diuresis: Cardiac amyloidosis patients are exquisitely preload-dependent. Aggressive diuresis can precipitate cardiogenic shock 1, 4

2. Ignoring autonomic dysfunction: These patients cannot compensate for volume shifts with normal autonomic responses 1, 4

3. Discontinuing therapy prematurely for creatinine elevation: Up to 30% increase is acceptable during effective decongestion and typically returns to baseline post-discharge 6, 7

4. Using conventional subcutaneous furosemide: Only pH-neutral formulations (like Furoscix) should be used; conventional preparations cause significant skin reactions 3

5. Applying standard heart failure protocols: Cardiac amyloidosis requires gentler, more cautious volume management than typical heart failure 1, 4

When Subcutaneous Route is Inappropriate

Subcutaneous furosemide is not appropriate for:

• Cardiogenic shock requiring urgent diuresis 11
• Severe renal dysfunction (creatinine >250 μmol/L or >50% increase from baseline) 7
• Patients requiring >240 mg furosemide equivalent daily 7
• Acute decompensation with end-organ hypoperfusion 11

These patients require hospitalization with intravenous therapy and intensive monitoring 6, 11.

Disease-Specific Therapy Integration

While managing volume status, ensure concurrent disease-modifying therapy:

• ATTR amyloidosis: Tafamidis (reduces mortality, HR 0.70) or vutrisiran (HR 0.72) 5, 13
• AL amyloidosis: Daratumumab-based chemotherapy 4, 13

Anticoagulation is indicated regardless of CHA₂DS₂-VASc score due to high intracardiac thrombus risk (approximately one-third of patients) 5.